Education
About Us
Working with TipRanks
Follow Us
Guardian Pharmacy Services, Inc. Class A (GRDN)
NYSE:GRDN
GRDN Stock Chart & Stats
$35.62
$0.47(2.39%)
At close: 4:00 PM EST
$35.62
$0.47(2.39%)
Day’s Range― - ―
52-Week Range$19.17 - $37.43
Previous Close$20.98
Volume93.63K
Average Volume (3M)348.83K
Market Cap
$2.26B
Enterprise Value$2.24B
Total Cash (Recent Filing)$65.62M
Total Debt (Recent Filing)$44.72M
Price to Earnings (P/E)38.1
Beta0.58
Next Earnings
May 18, 2026EPS Estimate
0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.37
Shares Outstanding36,253,742
10 Day Avg. Volume450,542
30 Day Avg. Volume348,833
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)9.12
Price to Sales (P/S)1.30
P/FCF Ratio23.26
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue1.54
Enterprise Value/Gross Profit7.93
Enterprise Value/Ebitda21.76
Forecast
1Y Price Target
$37.00Price Target Upside3.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)1.13
Revenue Forecast (FY)$1.42B
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistent positive operating and free cash flow (FCF rose to about $81M in 2025) provides durable internal funding for M&A, greenfield investments and working capital needs. Strong cash conversion supports reinvestment and balance-sheet repair, improving long-term resilience despite year-to-year variability.
Balance Sheet De-riskingA dramatic reduction in total debt and materially stronger equity by 2025 meaningfully lowers financial leverage and interest risk. Low net leverage increases strategic optionality to pursue disciplined M&A, absorb policy shocks, and fund operations without immediate external financing, strengthening multi‑quarter durability.
Scale & Market PenetrationMeaningful scale—rising residents served and strong script volume growth—drives durable demand, creates distribution leverage with long‑term care partners, and supports fixed‑cost absorption. Scale underpins improved gross profits and vaccine program economics, enhancing competitive positioning over the medium term.
Bears Say
Regulatory Pricing PressureThe Inflation Reduction Act (IRA) and related WAC reductions represent a structural revenue and pricing headwind (~$65M flagged for 2027). Mandatory price and reimbursement changes shrink addressable revenues and will require sustained margin offsetting or new services to preserve profitability over multiple years.
Earnings VolatilityA sharp 2024 loss followed by a 2025 rebound highlights operating volatility tied to payor dynamics and working capital swings. Persistent earnings variability undermines predictability of cash flow and complicates multi‑period planning, increasing the risk that one adverse year could pressure liquidity or capital allocation decisions.
Acquisition / Greenfield Margin DragEarly‑stage acquisitions and greenfield rollouts are currently dilutive (roughly 90bp margin drag), requiring time and capital to reach profitability. Extended ramp periods and integration execution risk can depress consolidated margins and delay expected returns, testing margin sustainability over the coming quarters.
Guardian Pharmacy Services, Inc. Class A News
GRDN FAQ
What was Guardian Pharmacy Services, Inc. Class A’s price range in the past 12 months?
Guardian Pharmacy Services, Inc. Class A lowest stock price was $19.17 and its highest was $37.43 in the past 12 months.
What is Guardian Pharmacy Services, Inc. Class A’s market cap?
Guardian Pharmacy Services, Inc. Class A’s market cap is $2.26B.
When is Guardian Pharmacy Services, Inc. Class A’s upcoming earnings report date?
Guardian Pharmacy Services, Inc. Class A’s upcoming earnings report date is May 18, 2026 which is in 56 days.
How were Guardian Pharmacy Services, Inc. Class A’s earnings last quarter?
Guardian Pharmacy Services, Inc. Class A released its earnings results on Mar 11, 2026. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of $0.268 by $0.102.
Is Guardian Pharmacy Services, Inc. Class A overvalued?
According to Wall Street analysts Guardian Pharmacy Services, Inc. Class A’s price is currently Undervalued.
Does Guardian Pharmacy Services, Inc. Class A pay dividends?
Guardian Pharmacy Services, Inc. Class A does not currently pay dividends.
What is Guardian Pharmacy Services, Inc. Class A’s EPS estimate?
Guardian Pharmacy Services, Inc. Class A’s EPS estimate is 0.24.
How many shares outstanding does Guardian Pharmacy Services, Inc. Class A have?
Guardian Pharmacy Services, Inc. Class A has 36,253,742 shares outstanding.
What happened to Guardian Pharmacy Services, Inc. Class A’s price movement after its last earnings report?
Guardian Pharmacy Services, Inc. Class A reported an EPS of $0.37 in its last earnings report, beating expectations of $0.268. Following the earnings report the stock price went down -0.716%.
Which hedge fund is a major shareholder of Guardian Pharmacy Services, Inc. Class A?
Currently, no hedge funds are holding shares in GRDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guardian Pharmacy Services, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.00 (3.87% Upside)
$37.00 (3.87% Upside)
Hedge Fund Trend
Decreased
By 81.9K Shares
Last Quarter.
Last Quarter.
News Sentiment
Bearish
Bullish news 33%
Bearish news 67%
Bearish news 67%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.50%
12-Months-Change
Fundamentals
Return on Equity
25.85%
Trailing 12-Months
Asset Growth
12.07%
Trailing 12-Months
Company Description
Guardian Pharmacy Services, Inc. Class A
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.
GRDN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized multiple strong operating and financial achievements—solid organic and reported revenue growth, meaningful adjusted EBITDA expansion, improved gross margins, strong cash generation, measurable clinical impact, and raised 2026 EBITDA guidance. Management acknowledged material industry headwinds from the IRA, one-time favorable Q4 variability, margin drag from early-stage acquisitions and greenfields, and ongoing operational complexity from new Medicare processes. Overall, the company appears to be executing well, generating cash, and positioning to offset near-term policy impacts, while remaining cautious and disciplined on M&A amid industry disruption.View all GRDN earnings summariesGRDN Stock 12 Month Forecast
Average Price Target
$37.00
▲(3.87% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---